Conclusions
toxicity
MUTANT
The combination of binimetinib and panitumumab had substantial toxicity and limited clinical activity for patients with mutant or WT This article reports the results of a study that evaluated the combination of the MEK1/2 inhibitor binimetinib and the EGFR inhibitor panitumumab in patients with 